Vaxcyte Welcomes Former Sanofi CEO to Board of Directors PCVX Stock News
| PCVX Stock | USD 33.73 0.01 0.03% |
Slightly above 54% of Vaxcyte's investor base is interested to short. The analysis of overall sentiment of trading Vaxcyte stock suggests that many investors are impartial at this time. Vaxcyte's investing sentiment can be driven by a variety of factors including economic data, Vaxcyte's earnings reports, geopolitical events, and overall market trends.
Vaxcyte has strengthened its leadership team by adding Dr. Olivier Brandicourt to its Board of Directors. Dr. Brandicourt brings extensive experience fro
Read at gurufocus.com
 |
Vaxcyte Fundamental Analysis
We analyze Vaxcyte's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vaxcyte using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vaxcyte based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Vaxcyte is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Vaxcyte Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Vaxcyte stock to make a market-neutral strategy. Peer analysis of Vaxcyte could also be used in its relative valuation, which is a method of valuing Vaxcyte by comparing valuation metrics with similar companies.
Peers
Vaxcyte Related Equities
| REPL | Replimune | 10.68 | ||||
| UTHR | United Therapeutics | 4.16 | ||||
| RVMD | Revolution Medicines | 3.25 | ||||
| ORIC | Oric Pharmaceuticals | 2.57 | ||||
| ASND | Ascendis Pharma | 1.33 | ||||
| NUVL | Nuvalent | 0.34 | ||||
| ITOS | Iteos Therapeutics | 0.1 | ||||
| GBIO | Generation Bio | 0.44 | ||||
| RLAY | Relay Therapeutics | 3.29 | ||||
| VTYX | Ventyx Biosciences | 5.15 |
Additional Tools for Vaxcyte Stock Analysis
When running Vaxcyte's price analysis, check to measure Vaxcyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxcyte is operating at the current time. Most of Vaxcyte's value examination focuses on studying past and present price action to predict the probability of Vaxcyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxcyte's price. Additionally, you may evaluate how the addition of Vaxcyte to your portfolios can decrease your overall portfolio volatility.